StartseitevorwärtsAktienvorwärtsDianthus TherapeuticsvorwärtsNachrichten
    Dianthus Therapeutics Aktie
    Aktie
    ISIN: US2528281080 WKN: A3ERZ4 SYM: 87E Land Flagge US USA
    Zur Watchlist hinzufügenZur Watchlist hinzufügen Zum Portfolio hinzufügenZum Portfolio hinzufügen
    31,60
     
    EUR
    0,00 %
    0,00 EUR
    Letzter Kurs 07.11.25 Tradegate

    Dianthus Therapeutics Aktie kaufen

    Geldkurs
    07.11.25
    31,20
     
    EUR
    192 STK
    Briefkurs
    07.11.25
    31,60
     
    EUR
    189 STK
    Verkauf
    Kauf
    BEI SMARTBROKER+ HANDELN
    Hinweis
    Verlängerte Handelszeiten
    Ab sofort von 07:30 bis 23:00 Uhr
    Baader Tragding

    Neueste Nachrichten

    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
    05.11.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics to Participate in Four Investor Conferences During November
    04.11.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
    29.10.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
    16.10.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
    02.10.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    11.09.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
    10.09.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
    08.09.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile
    08.09.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis
    08.09.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
    07.08.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht
    Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
    29.05.25 · globenewswire · Dianthus TherapeuticsEnglische Nachricht